Phreesia (NYSE:PHR) received a $33.00 price objective from stock analysts at Piper Jaffray Companies in a research note issued to investors on Tuesday, TipRanks reports. The brokerage presently has a “buy” rating on the stock. Piper Jaffray Companies’ target price indicates a potential upside of 28.86% from the stock’s previous close.

A number of other research analysts have also recently weighed in on the company. Chardan Capital began coverage on Phreesia in a research note on Tuesday, July 23rd. They set a “buy” rating and a $33.00 price target for the company. Wells Fargo & Co started coverage on shares of Phreesia in a research report on Monday, August 12th. They set an “outperform” rating and a $23.00 price target on the stock. JPMorgan Chase & Co. began coverage on shares of Phreesia in a report on Tuesday, August 13th. They issued an “overweight” rating and a $33.00 price objective on the stock. Finally, William Blair began coverage on Phreesia in a report on Monday, August 12th. They issued an “outperform” rating for the company. Five equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $30.50.

Shares of Phreesia stock traded up $0.29 on Tuesday, hitting $25.61. The stock had a trading volume of 184,581 shares, compared to its average volume of 279,973. The business has a 50 day moving average price of $26.67. Phreesia has a 52-week low of $22.05 and a 52-week high of $29.38.

In related news, major shareholder Ii L.P. Chv sold 335,767 shares of Phreesia stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $18.00, for a total value of $6,043,806.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Scott Perricelli sold 743,388 shares of the firm’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $18.00, for a total value of $13,380,984.00. The disclosure for this sale can be found here.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.

Further Reading: How does a 12b-1 fee affect fund performance?

Analyst Recommendations for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.